Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769467 · ClinicalTrials.gov registry record · Phase 1
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
A Phase 1 study, sponsored by Atara Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03769467 is a Phase 1 study that was terminated before completion, run by Atara Biotherapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03769467, a Phase 1 study, was terminated before completion, sponsored by Atara Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Tabelecleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2021-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03769467
The ClinicalTrials.gov registry entry for NCT03769467 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atara Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03769467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03769467 about?
NCT03769467 is a clinical study titled "Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)". This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).
What is the current status of trial NCT03769467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-02-19. Estimated completion is 2021-08-19.
What interventions are being tested in trial NCT03769467?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Tabelecleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03769467?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.